Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases

Recombinant activated factor VII (rFVIIa) is the bypassing agent used in the first-line hemostatic therapy for acquired hemophilia A (AHA); however, the occurrence of thrombotic complications in rFVIIa-treated AHA patients was recently reported to be 2.9–6.5%. Therefore, the investigation of the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Makoto, Kanaya, Minoru, Izumiyama, Koh, Mori, Akio, Irie, Tatsuro, Tanaka, Masanori, Morioka, Masanobu, Ieko, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098745/
https://www.ncbi.nlm.nih.gov/pubmed/27843336
http://dx.doi.org/10.2147/IJGM.S118422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098745/
https://www.ncbi.nlm.nih.gov/pubmed/27843336
http://dx.doi.org/10.2147/IJGM.S118422

Ejemplares similares